ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Clascoterone

Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.

Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.

Drug pageClascoterone: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 17, 201519 company-led studies, 3 open or runningNext primary completion: Aug 7, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cassiopea SpAits history only70 open or runningphase 3since Nov 17, 2015Nov 17, 2015none ahead
Sun Pharmaceutical Industriesits history only61 open or runningphase 4since Mar 11, 2024Mar 11, 2024none ahead
3SBio32 open or runningphase 3since Apr 30, 2024Apr 30, 2024Aug 7, 2028phase 3 · NCT07457294
Intrepid Therapeuticsits history only30 open or runningphase 2since Jun 27, 2012Jun 27, 2012none ahead

Also a collaborator on its studies: Canfield Scientific and ICON Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of 3SBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named clascoteroneINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Apr 30, 2024First study: phase 3 study in Acne VulgarisFirst studyNCT06403501 · 692 planned · China
  3. May 31, 2024Phase 1 study in Acne VulgarisNCT06454708 · 12 enrolled · China
  4. Feb 26, 2026Phase 3 study in Acne VulgarisNCT07457294 · 692 planned

Ahead

  1. Aug 7, 2028Primary completion: phase 3 study in Acne VulgarisNCT07457294

TargetBeta

AR →read by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 3 3SBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07457294Acne Vulgaris3Not yet recruitingAug 7, 2028692
NCT06454708Acne Vulgaris · China1CompletedAug 12, 202412
NCT06403501Acne Vulgaris · China3RecruitingOct 2026692

How it is read

Names in the registry

  • “Winlevi (clascoterone) 1% cream”, 3 entries
  • “CB-03-01 cream, 1%”, 3 entries
  • “Clascoterone 5% solution”, 2 entries
  • “cortexolone 17α-propionate”, 2 entries
  • “CB-03-01”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.